ACP3
Prostatic acid phosphatase
As of the edition of 20 October 2026, ACP3 (prostatic acid phosphatase, UniProt P15309) has 2 drugs tested at it and 2 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P15309
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 17
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health
- Registered trials of its drugs
- 32
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| SIPULEUCEL-T | Marketed | Phase 3 | Ended 2022 |
| Autologous peripheral-blood mononuclear cells including a minimum of 50 million autologous cd54+ cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor | Marketed | Phase 2 | Ended 2022 |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 2 |
| Total on the list | 2 |